Our Company

AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers in order to both detect and neutralize them throughout disease progression. AltPep’s emphasis is on early, pre-symptomatic detection and treatment.

Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.

Decades of scientific research by the Daggett Research Group at the University of Washington provided the foundation for AltPep’s innovative approach.